{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:01:13Z","timestamp":1776078073873,"version":"3.50.1"},"reference-count":68,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The cancers of the cervix, endometrium, ovary, and breast are great threats\nto women\u2019s health. Cancer is characterized by the uncontrolled proliferation of cells and\nderegulated cell cycle progression is one of the main causes of malignancy. Agents\ntargeting cell cycle regulators may have potential anti-tumor effects. CDC20 (cell division\ncycle 20 homologue) is a co-activator of the anaphase-promoting complex\/cyclosome\n(APC\/C) and thus acts as a mitotic regulator. In addition, CDC20 serves as a subunit of\nthe mitotic checkpoint complex (MCC) whose function is to inhibit APC\/C. Recently,\nhigher expression of CDC20 has been reported in these cancers and was closely\nassociated with their clinicopathological parameters, indicating CDC20 a potential target\nfor cancer treatment that is worth further study. In the present review, we summarized\ncurrent progress and put forward perspectives of CDC20 in female reproductive\ncancers.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573405618666220321130102","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T20:01:56Z","timestamp":1647979316000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current Progress and Perspectives of CDC20 in Female\nReproductive Cancers"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-7634","authenticated-orcid":true,"given":"Ke","family":"Ni","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","volume":"33","author":"Eggersmann T.K.","year":"2019","unstructured":"Eggersmann T.K.; Degenhardt T.; Gluz O.; Wuerstlein R.; Harbeck N.; CDK4\/6 inhibitors expand the therapeutic options in breast cancer: Palbociclib, ribociclib and abemaciclib. BioDrugs 2019,33(2),125-135","journal-title":"BioDrugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tibs.2005.02.004","volume":"30","author":"Hoppe T.","year":"2005","unstructured":"Hoppe T.; Multiubiquitylation by E4 enzymes: \u2018One size\u2019 doesn\u2019t fit all. Trends Biochem Sci 2005,30(4),183-187","journal-title":"Trends Biochem Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrc1994","volume":"6","author":"Hoeller D.","year":"2006","unstructured":"Hoeller D.; Hecker C.M.; Dikic I.; Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006,6(10),776-788","journal-title":"Nat Rev Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF02705243","volume":"31","author":"Nandi D.","year":"2006","unstructured":"Nandi D.; Tahiliani P.; Kumar A.; Chandu D.; The ubiquitin-proteasome system. J Biosci 2006,31(1),137-155","journal-title":"J Biosci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1126\/science.278.5337.460","volume":"278","author":"Visintin R.","year":"1997","unstructured":"Visintin R.; Prinz S.; Amon A.; CDC20 and CDH1: A family of substrate-specific activators of APC-dependent proteolysis. Science 1997,278(5337),460-463","journal-title":"Science"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/10049","volume":"1","author":"Clute P.","year":"1999","unstructured":"Clute P.; Pines J.; Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999,1(2),82-87","journal-title":"Nat Cell Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.molcel.2007.06.013","volume":"27","author":"Amador V.","year":"2007","unstructured":"Amador V.; Ge S.; Santamar\u00eda P.G.; Guardavaccaro D.; Pagano M.; APC\/C(CDC20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 2007,27(3),462-473","journal-title":"Mol Cell"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"32988","DOI":"10.1074\/jbc.M110.140905","volume":"285","author":"Cui Y.","year":"2010","unstructured":"Cui Y.; Cheng X.; Zhang C.; Degradation of the Human Mitotic Checkpoint Kinase Mps1 Is Cell Cycle-regulated by APC-C(CDC20) and APC-c(Cdh1). Ubiquitin Ligases J Biol Chem 2010,285(43),32988-32998","journal-title":"Ubiquitin Ligases J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1083\/jcb.153.1.137","volume":"153","author":"Geley S.","year":"2001","unstructured":"Geley S.; Kramer E.; Gieffers C.; Gannon J.; Peters J.M.; Hunt T.; Anaphase-promoting complex\/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 2001,153(1),137-148","journal-title":"J Cell Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1242\/jcs.062075","volume":"123","author":"Gurden M.D.J.","year":"2010","unstructured":"Gurden M.D.J.; Holland A.J.; van Zon W.; CDC20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F. J Cell Sci 2010,123(Pt 3),321-330","journal-title":"J Cell Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb1410","volume":"8","author":"Hayes M.J.","year":"2006","unstructured":"Hayes M.J.; Kimata Y.; Wattam S.L.; Early mitotic degradation of Nek2A depends on CDC20-independent interaction with the APC\/C. Nat Cell Biol 2006,8(6),607-614","journal-title":"Nat Cell Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1083\/jcb.200102093","volume":"154","author":"Sudakin V.","year":"2001","unstructured":"Sudakin V.; Chan G.K.T.; Yen T.J.; Checkpoint inhibition of the APC\/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001,154(5),925-936","journal-title":"J Cell Biol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"R966","DOI":"10.1016\/j.cub.2012.10.006","volume":"22","author":"Lara-Gonzalez P.","year":"2012","unstructured":"Lara-Gonzalez P.; Westhorpe F.G.; Taylor S.S.; The spindle assembly checkpoint. Curr Biol 2012,22(22),R966-R980","journal-title":"Curr Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"Cory S.","year":"2002","unstructured":"Cory S.; Adams J.M.; The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002,2(9),647-656","journal-title":"Nat Rev Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.devcel.2014.04.022","volume":"29","author":"Wan L.","year":"2014","unstructured":"Wan L.; Tan M.; Yang J.; APC(CDC20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell 2014,29(4),377-391","journal-title":"Dev Cell"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/emboj.2010.112","volume":"29","author":"Harley M.E.","year":"2010","unstructured":"Harley M.E.; Allan L.A.; Sanderson H.S.; Clarke P.R.; Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its CDC20-dependent destruction during mitotic arrest. EMBO J 2010,29(14),2407-2420","journal-title":"EMBO J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.bbrc.2011.10.146","volume":"415","author":"Wang R.","year":"2011","unstructured":"Wang R.; Li K.M.; Zhou C.H.; Xue J.L.; Ji C.N.; Chen J.Z.; CDC20 mediates D-box-dependent degradation of Sp100. Biochem Biophys Res Commun 2011,415(4),702-706","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1126\/science.1177087","volume":"326","author":"Yang Y.","year":"2009","unstructured":"Yang Y.; Kim A.H.; Yamada T.; A CDC20-APC ubiquitin signaling pathway regulates presynaptic differentiation. Science 2009,326(5952),575-578","journal-title":"Science"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cell.2008.11.050","volume":"136","author":"Kim A.H.","year":"2009","unstructured":"Kim A.H.; Puram S.V.; Bilimoria P.M.; A centrosomal CDC20-APC pathway controls dendrite morphogenesis in postmitotic neurons. Cell 2009,136(2),322-336","journal-title":"Cell"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","volume":"382","author":"Crosbie E.J.","year":"2013","unstructured":"Crosbie E.J.; Einstein M.H.; Franceschi S.; Kitchener H.C.; Human papillomavirus and cervical cancer. Lancet 2013,382(9895),889-899","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2407-11-80","volume":"11","author":"Rajkumar T.","year":"2011","unstructured":"Rajkumar T.; Sabitha K.; Vijayalakshmi N.; Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011,11(1),80","journal-title":"BMC Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/PGP.0000000000000082","volume":"33","author":"Kim Y.","year":"2014","unstructured":"Kim Y.; Choi J.W.; Lee J.H.; Kim Y.S.; MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol 2014,33(5),517-523","journal-title":"Int J Gynecol Pathol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s13277-015-3808-1","volume":"37","author":"Gayyed M.F.","year":"2016","unstructured":"Gayyed M.F.; El-Maqsoud N.M.; Tawfiek E.R.; El Gelany S.A.; Rahman M.F.; A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: Its correlation with tumor grade and stage. Tumour Biol 2016,37(1),749-762","journal-title":"Tumour Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e55975","DOI":"10.1371\/journal.pone.0055975","volume":"8","author":"Espinosa A.M.","year":"2013","unstructured":"Espinosa A.M.; Alfaro A.; Roman-Basaure E.; Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 2013,8(2),e55975","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.1128\/JVI.00259-10","volume":"84","author":"Patel D.","year":"2010","unstructured":"Patel D.; McCance D.J.; Compromised spindle assembly checkpoint due to altered expression of Ubch10 and CDC20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J Virol 2010,84(21),10956-10964","journal-title":"J Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.4161\/cc.4.11.2123","volume":"4","author":"Bellanger S.","year":"2005","unstructured":"Bellanger S.; Blachon S.; Mechali F.; Bonne-Andrea C.; Thierry F.; High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and CDC20 and cause genomic instability. Cell Cycle 2005,4(11),1608-1615","journal-title":"Cell Cycle"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1080\/15384101.2015.1021519","volume":"14","author":"Tan C.L.","year":"2015","unstructured":"Tan C.L.; Teissier S.; Gunaratne J.; Quek L.S.; Bellanger S.; Stranglehold on the spindle assembly checkpoint: The human papillomavirus E2 protein provokes BUBR1-dependent aneuploidy. Cell Cycle 2015,14(9),1459-1470","journal-title":"Cell Cycle"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1568009620666200621153831","volume":"20","author":"Vadlamudi Y.","year":"2020","unstructured":"Vadlamudi Y.; Dey D.K.; Kang S.C.; Emerging multi-cancer regulatory role of ESRP1: Orchestration of alternative splicing to control EMT. Curr Cancer Drug Targets 2020,20(9),654-665","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"E3705","DOI":"10.3390\/ijms20153705","volume":"20","author":"Chen Z.H.","year":"2019","unstructured":"Chen Z.H.; Jing Y.J.; Yu J.B.; ESRP1 induces cervical cancer cell g1-phase arrest via regulating cyclin A2 mRNA stability. Int J Mol Sci 2019,20(15),E3705","journal-title":"Int J Mol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/cncr.30094","volume":"122","author":"McAlpine J.N.","year":"2016","unstructured":"McAlpine J.N.; Temkin S.M.; Mackay H.J.; Endometrial cancer: Not your grandmother\u2019s cancer. Cancer 2016,122(18),2787-2798","journal-title":"Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9924","DOI":"10.1038\/s41598-019-46195-8","volume":"9","author":"Huo X.","year":"2019","unstructured":"Huo X.; Sun H.; Cao D.; Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data. Sci Rep 2019,9(1),9924","journal-title":"Sci Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"Ledermann J.A.","year":"2016","unstructured":"Ledermann J.A.; Embleton A.C.; Raja F.; Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016,387(10023),1066-1074","journal-title":"Lancet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ijc.21902","volume":"119","author":"Ouellet V.","year":"2006","unstructured":"Ouellet V.; Guyot M.C.; Le Page C.; Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006,119(3),599-607","journal-title":"Int J Cancer"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"42983","DOI":"10.18632\/oncotarget.17785","volume":"8","author":"Sun Q.","year":"2017","unstructured":"Sun Q.; Zhao H.; Zhang C.; Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers. Oncotarget 2017,8(26),42983-42996","journal-title":"Oncotarget"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1080\/21655979.2021.1939514","volume":"12","author":"Sun X.","year":"2021","unstructured":"Sun X.; Liu Q.; Huang J.; Diao G.; Liang Z.; Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer. Bioengineered 2021,12(1),3753-3771","journal-title":"Bioengineered"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13048-020-0613-2","volume":"13","author":"Yang D.","year":"2020","unstructured":"Yang D.; He Y.; Wu B.; Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer. J Ovarian Res 2020,13(1),10","journal-title":"J Ovarian Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13048-020-00680-1","volume":"13","author":"Fei H.","year":"2020","unstructured":"Fei H.; Chen S.; Xu C.; Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways. J Ovarian Res 2020,13(1),82","journal-title":"J Ovarian Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13048-021-00837-6","volume":"14","author":"Dong C.","year":"2021","unstructured":"Dong C.; Tian X.; He F.; Integrative analysis of key candidate genes and signaling pathways in ovarian cancer by bioinformatics. J Ovarian Res 2021,14(1),92","journal-title":"J Ovarian Res"},{"key":"ref=40","first-page":"6527","volume":"18","author":"Li D.F.","year":"2021","unstructured":"Li D.F.; Tulahong A.; Uddin M.N.; Zhao H.; Zhang H.; Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer. Math Biosci Eng 2021,18(5),6527-6551","journal-title":"Math Biosci Eng"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/JCMA.0000000000000313","volume":"83","author":"Kang Y.M.","year":"2020","unstructured":"Kang Y.M.; Lan A.; Huang Y.H.; Hsu K.M.; Chao Y.; Lan K.L.; Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools. J Chin Med Assoc 2020,83(5),446-453","journal-title":"J Chin Med Assoc"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s12282-021-01242-z","volume":"28","author":"Song C.","year":"2021","unstructured":"Song C.; Lowe V.J.; Lee S.; Inhibition of CDC20 suppresses the metastasis in triple negative breast cancer (TNBC). Breast Cancer 2021,28(5),1073-1086","journal-title":"Breast Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1078-0432.CCR-05-0903","volume":"12","author":"Yuan B.","year":"2006","unstructured":"Yuan B.; Xu Y.; Woo J.H.; Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006,12(2),405-410","journal-title":"Clin Cancer Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-019-05420-8","volume":"178","author":"Alfarsi L.H.","year":"2019","unstructured":"Alfarsi L.H.; Ansari R.E.; Craze M.L.; CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Res Treat 2019,178(3),535-544","journal-title":"Breast Cancer Res Treat"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"BSR20191227","DOI":"10.1042\/BSR20191227","volume":"40","author":"Cheng L.","year":"2020","unstructured":"Cheng L.; Huang Y.Z.; Chen W.X.; Cell division cycle proteinising prognostic biomarker of breast cancer. Biosci Rep 2020,40(5),BSR20191227","journal-title":"Biosci Rep"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7150\/jca.48245","volume":"12","author":"Hong Z.","year":"2021","unstructured":"Hong Z.; Wang Q.; Hong C.; Identification of seven cell cycle-related genes with unfavorable prognosis and construction of their TF-miRNA-mRNA regulatory network in Breast Cancer. J Cancer 2021,12(3),740-753","journal-title":"J Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/gtmb.2020.0047","volume":"24","author":"Wu J.","year":"2020","unstructured":"Wu J.; Lv Q.; Huang H.; Zhu M.; Meng D.; Screening and identification of key biomarkers in inflammatory breast cancer through integrated bioinformatic analyses. Genet Test Mol Biomarkers 2020,24(8),484-491","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"12431","DOI":"10.1080\/21655979.2021.2005747","volume":"12","author":"Wang N.","year":"2021","unstructured":"Wang N.; Zhang H.; Li D.; Jiang C.; Zhao H.; Teng Y.; Identification of novel biomarkers in breast cancer via integrated bioinformatics analysis and experimental validation. Bioengineered 2021,12(2),12431-12446","journal-title":"Bioengineered"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3892\/ijo.2019.4791","volume":"54","author":"Cheng S.","year":"2019","unstructured":"Cheng S.; Castillo V.; Sliva D.; CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity. Int J Oncol 2019,54(6),2250-2256","journal-title":"Int J Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fbioe.2015.00014","volume":"3","author":"Parmar M.B.","year":"2015","unstructured":"Parmar M.B.; Aliabadi H.M.; Mahdipoor P.; Targeting cell cycle proteins in breast cancer cells with sirna by using lipid-substituted polyethylenimines. Front Bioeng Biotechnol 2015,3,14","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/CBM-210199","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Identification of potential prognostic markers associated with lung metastasis in breast cancer by coexpression network analysis. Cancer Biomark 2021,1-12","journal-title":"Cancer Biomark"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/bjc.2014.252","volume":"110","author":"Karra H.","year":"2014","unstructured":"Karra H.; Repo H.; Ahonen I.; CDC20 and securin overexpression predict short-term breast cancer survival. Br J Cancer 2014,110(12),2905-2913","journal-title":"Br J Cancer"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1038\/cddis.2017.270","volume":"8","author":"Paul D.","year":"2017","unstructured":"Paul D.; Ghorai S.; Dinesh U.S.; Shetty P.; Chattopadhyay S.; Santra M.K.; CDC20 directs proteasome-mediated degradation of the tumor suppressor SMAR1 in higher grades of cancer through the anaphase promoting complex. Cell Death Dis 2017,8(6),e2882","journal-title":"Cell Death Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2174\/1566524011313040014","volume":"13","author":"Bellati F.","year":"2013","unstructured":"Bellati F.; Napoletano C.; Ruscito I.; Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med 2013,13(4),648-669","journal-title":"Curr Mol Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pharmthera.2015.04.002","volume":"151","author":"Wang L.","year":"2015","unstructured":"Wang L.; Zhang J.; Wan L.; Zhou X.; Wang Z.; Wei W.; Targeting CDC20 as a novel cancer therapeutic strategy. Pharmacol Ther 2015,151,141-151","journal-title":"Pharmacol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3892\/mmr.2014.2907","volume":"11","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Yang B.; Zhou K.; Potential therapeutic mechanism of genistein in breast cancer involves inhibition of cell cycle regulation. Mol Med Rep 2015,11(3),1820-1826","journal-title":"Mol Med Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1158\/0008-5472.CAN-13-2081","volume":"74","author":"Nagalingam A.","year":"2014","unstructured":"Nagalingam A.; Kuppusamy P.; Singh S.V.; Sharma D.; Saxena N.K.; Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Cancer Res 2014,74(9),2617-2629","journal-title":"Cancer Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bbrc.2011.10.055","volume":"415","author":"Jiang J.","year":"2011","unstructured":"Jiang J.; Jedinak A.; Sliva D.; Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. Biochem Biophys Res Commun 2011,415(2),325-329","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e34283","DOI":"10.1371\/journal.pone.0034283","volume":"7","author":"Jiang J.","year":"2012","unstructured":"Jiang J.; Thyagarajan-Sahu A.; Krch\u0148\u00e1k V; Jedinak A; Sandusky GE; Sliva D.; NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS One 2012,7(3),e34283","journal-title":"PLoS One"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bbrc.2021.07.047","volume":"570","author":"Yamashita N.","year":"2021","unstructured":"Yamashita N.; Yoshizuka A.; Kase A.; Activation of the aryl hydrocarbon receptor by 3-methylcholanthrene, but not by indirubin, suppresses mammosphere formation via downregulation of CDC20 expression in breast cancer cells. Biochem Biophys Res Commun 2021,570,131-136","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/ph14100957","volume":"14","author":"Egorova A.","year":"2021","unstructured":"Egorova A.; Pyankov I.; Maretina M.; Baranov V.; Kiselev A.; Peptide nanoparticle-mediated combinatorial delivery of cancer-related sirnas for synergistic anti-proliferative activity in triple negative breast cancer cells. Pharmaceuticals (Basel) 2021,14(10),957","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"23702","DOI":"10.18632\/aging.203642","volume":"13","author":"Liu N.","year":"2021","unstructured":"Liu N.; Wang X.; Zhu Z.; Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology. Aging (Albany NY) 2021,13(20),23702-23725","journal-title":"Aging (Albany NY)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-019-0700-2","volume":"12","author":"Li M.","year":"2019","unstructured":"Li M.; Li A.; Zhou S.; Lv H.; Yang W.; SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol 2019,12(1),14","journal-title":"J Hematol Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccr.2011.09.004","volume":"20","author":"Kim H.S.","year":"2011","unstructured":"Kim H.S.; Vassilopoulos A.; Wang R.H.; SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC\/C activity. Cancer Cell 2011,20(4),487-499","journal-title":"Cancer Cell"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/sj.onc.1210799","volume":"27","author":"Kidokoro T.","year":"2008","unstructured":"Kidokoro T.; Tanikawa C.; Furukawa Y.; Katagiri T.; Nakamura Y.; Matsuda K.; CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 2008,27(11),1562-1571","journal-title":"Oncogene"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ccr.2010.08.010","volume":"18","author":"Zeng X.","year":"2010","unstructured":"Zeng X.; Sigoillot F.; Gaur S.; Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010,18(4),382-395","journal-title":"Cancer Cell"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.2174\/1381612811319180005","volume":"19","author":"Wang Z.","year":"2013","unstructured":"Wang Z.; Wan L.; Zhong J.; CDC20: A potential novel therapeutic target for cancer treatment. Curr Pharm Des 2013,19(18),3210-3214","journal-title":"Curr Pharm Des"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fonc.2011.00060","volume":"1","author":"Penas C.","year":"2012","unstructured":"Penas C.; Ramachandran V.; Ayad N.G.; The APC\/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol 2012,1,60","journal-title":"Front Oncol"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573405618666220321130102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202467\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573405618666220321130102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:36:06Z","timestamp":1693809366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202467\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573405618666220321130102","relation":{},"ISSN":["1566-5240"],"issn-type":[{"value":"1566-5240","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}